BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 33769624)

  • 21. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
    Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
    Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study.
    Søreide JA; Kvaløy JT; Lea D; Sandvik OM; Al-Saiddi M; Haslerud TM; Garresori H; Karlsen LN; Gudlaugsson E; Søreide K
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1462. PubMed ID: 34105314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
    Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
    J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
    Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
    Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
    Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
    Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
    Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
    Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
    Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
    Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
    Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
    J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
    Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
    Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
    Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
    [No Abstract]   [Full Text] [Related]  

  • 40. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
    Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
    J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.